Nov 22 2011
In a pressed economic climate, the estimated 3 million chronic wounds treated every year costs the German health care system several billion Euros, a situation fuelled by an annual prevalence of 650,000 new patients. This creates an immense cost pressure on everyone involved in wound care, in a market already characterised by tough competition, ever changing political framework and an expectation of innovation and improved quality of care.
In order to meet these demands Systagenix and TRIGOcare have partnered up to deliver a full portfolio of wound care products to suit the varying needs of the market. TRIGOcare is the first supplier of generic medical devices to offer high quality products at competitive prices. Together Systagenix and TRIGOcare offer a complete assortment of wound care products to meet the needs of any care model in every price segment. This brand cooperation will provide a comprehensive spectrum of innovative products and services which should help address the individual needs of doctors, nurses and patients.
Home of Let's Heal® and focused 100% in wound care; Systagenix Wound Management GmbH is already a leading supplier of advanced wound care solutions in Germany. Committed to improving patient outcomes through the application of point of care diagnostics and targeted therapies, the company expects to launch the world's first point of care test able to detect elevated protease activity (EPA) later this year. EPA is an indicator of stalled healing in chronic wounds, the management of which is a major burden on annual healthcare budgets.
TRIGOcare GmbH offers its customers a comprehensive range of products to manage each phase of the moist wound healing process. The products can be used in combination and allow a broad variety of applications.
Source: Systagenix
Innovative injectable filler offers hope for diabetic wound treatment